Search

Your search keyword '"Redondo, Andrés"' showing total 162 results
Start Over Author "Redondo, Andrés" Language english
162 results on '"Redondo, Andrés"'

2. Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor

Author

Carrillo-García, Jaime, Hindi, Nadia, Conceicao, Magda, Sala, María Ángeles, Ugalde, Aitziber, López-Pousa, Antonio, Bagué, Silvia, Sevilla, Isabel, Vicioso, Luis, Ramos, Rafael, Martínez-Trufero, Javier, Gómez Mateo, M<ce:sup loc='post">a</ce:sup> Carmen, Cruz, Josefina, Hernández-León, Carmen Nieves, Redondo, Andrés, Mendiola, Marta, García, Jerónimo Martínez, Hernández, José Emilio, Álvarez, Rosa, Agra, Carolina, de Juan-Ferré, Ana, Valverde, Claudia, Cano, Juana María, Sande, Luis Miguel de, Pérez-Fidalgo, José A., Lavernia, Javier, Marcilla, David, Gutiérrez, Antonio, Moura, David S., and Martín-Broto, Javier

Published
2024
Full Text
View/download PDF

3. Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016–01)

Author

García-Donas, Jesus, Redondo, Andres, Santaballa, Ana, Garrigos, Laia, Rubio, Mª. Jesus, Lainez, Nuria, González, María Iglesias, Cueva, Juan Fernando, Barquin, Arantzazu, Grazioso, Tatiana P., Hurtado, Alicia, Sevillano, Elena, Grande, Enrique, Rodriguez-Moreno, Juan Francisco, and Navarro, Paloma

Published
2024
Full Text
View/download PDF

5. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

Author

Harter, Philipp, Bogner, Gerhard, Chiva, Luis, Cibula, David, Concin, Nicole, Fotopoulou, Christina, Gonzalez-Martin, Antonio, Guyon, Frederic, Heinzelmann-Schwarz, Viola, Kridelka, Frederic, Mahner, Sven, Marmé, Frederik, Marth, Christian, Morice, Philippe, Novák, Zoltán, Papadia, Andrea, Ray-Coquard, Isabelle, Redecha, Mikuláš, Redondo, Andres, Schwameis, Richard, Sehouli, Jalid, Undurraga, Manuela, Van Gorp, Toon, and Vergote, Ignace

Published
2024
Full Text
View/download PDF

6. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Abadie-Lacourtoisie, Sophie, Andreetta, Claudia, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bellier, Charlotte, Bentzen, Anne Gry, Berton, Dominique, Billemont, Bertrand, Bjørge, Line, Bjurberg, Maria, Black, Destin, Bologna, Alessandra, Braicu, Elena Ioana, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Guerra, Eva, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Minobe, Shinichiro, Moxley, Katherine, Nagao, Shoji, Nicoletto, Ornella, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pérez-Fidalgo, J Alejandro, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Redondo, Andrés, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tasca, Giulia, Tewari, Krishnansu, Todo, Yukiharu, Valabrega, Giorgio, Wimberger, Pauline, Woelber, Linn, Yamaguchi, Satoshi, You, Benoît, Yunokawa, Mayu, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, De Giorgi, Ugo, Lindemann, Kristina, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Angelergues, Antoine, Fariñas-Madrid, Lorena, Lorusso, Domenica, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Lebreton, Coriolan, Dahlstrand, Hanna, D'Hondt, Véronique, and Randall, Leslie M

Published
2024
Full Text
View/download PDF

7. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

Author

González-Martín, Antonio, Pothuri, Bhavana, Vergote, Ignace, Graybill, Whitney, Lorusso, Domenica, McCormick, Colleen C., Freyer, Gilles, Backes, Floor, Heitz, Florian, Redondo, Andrés, Moore, Richard G., Vulsteke, Christof, O'Cearbhaill, Roisin E., Malinowska, Izabela A., Shtessel, Luda, Compton, Natalie, Mirza, Mansoor R., and Monk, Bradley J.

Published
2023
Full Text
View/download PDF

11. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Author

Raspagliesi, Francesco, Melichar, Bohuslav, Gaba Garcia, Lydia, Jackson, Amanda, Henry, Stephanie, Kral, Zdenek, Harter, Philipp, De Giorgi, Ugo, Bjurberg, Maria, Gold, Michael, O'Malley, David, Honhon, Brigitte, Vulsteke, Christof, De Cuypere, Eveline, Denys, Hannelore, Baurain, Jean-Francois, Zamagni, Claudio, Tenney, Meaghan, Gordinier, Mary, Bradley, William, Schlumbrecht, Matthew, Spirtos, Nicola, Concin, Nicole, Mahner, Sven, Scambia, Giovanni, Leath, Charles, Farias-Eisner, Robin, Cohen, Joshua, Muller, Carolyn, Bhatia, Sumeet, Coleman, Robert L, Lorusso, Domenica, Gennigens, Christine, González-Martín, Antonio, Randall, Leslie, Cibula, David, Lund, Bente, Woelber, Linn, Pignata, Sandro, Forget, Frederic, Redondo, Andrés, Vindeløv, Signe Diness, Chen, Menghui, Harris, Jeffrey R, Smith, Margaret, Nicacio, Leonardo Viana, Teng, Melinda S L, Laenen, Annouschka, Rangwala, Reshma, Manso, Luis, Mirza, Mansoor, Monk, Bradley J, and Vergote, Ignace

Published
2021
Full Text
View/download PDF

12. Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary.

Author

González-Martín, Antonio, Pothuri, Bhavana, Vergote, Ignace, Graybill, Whitney, Lorusso, Domenica, McCormick, Colleen C, Freyer, Gilles, Backes, Floor, Heitz, Florian, Redondo, Andrés, Moore, Richard G, Vulsteke, Christof, O'Cearbhaill, Roisin E, Malinowska, Izabela A, Shtessel, Luda, Compton, Natalie, Mirza, Mansoor R, and Monk, Bradley J

Abstract

Plain Language Summary What is this summary about? This PLSP provides a short summary of an original scientific article that presented results from the PRIMA study after 3.5 years of follow-up time. The original article was published in the European Journal of Cancer in 2023. The PRIMA study included adult patients with newly diagnosed advanced high-risk ovarian cancer whose tumors shrunk or became undetectable after treatment with chemotherapy with or without surgery. The PRIMA study evaluated how well the drug niraparib, also known as Zejula, worked at delaying or preventing ovarian cancer from coming back (recurring) or getting worse (progressing) compared with placebo (a substance with no effects that a doctor gives to a patient instead of a drug). The first results from the PRIMA study were published in 2019, when patients had participated in the PRIMA study for about 1.2 years. The article this PLSP is based on reports longer-term data from the PRIMA study, when patients had participated in the PRIMA study for about 3.5 years. Patients were monitored (or followed) for a longer time to understand how well niraparib continued to work and to evaluate whether the safety of niraparib changed with additional time being monitored. What were the results? Patients who took niraparib had more time before their cancer came back or got worse than patients who took placebo. In terms of safety, no new types of side effects with niraparib treatment were observed with additional time being monitored as part of the PRIMA study. What do the results mean? These results support that niraparib remains an important treatment option to help delay the cancer from coming back or getting worse in patients with newly diagnosed advanced ovarian cancer that responded to initial treatment. Clinical Trial Registration:NCT02655016 (PRIMA study) (ClinicalTrials.gov) [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial

Author

Martin-Broto, Javier, Cruz, Josefina, Penel, Nicolas, Le Cesne, Axel, Hindi, Nadia, Luna, Pablo, Moura, David S, Bernabeu, Daniel, de Alava, Enrique, Lopez-Guerrero, Jose Antonio, Dopazo, Joaquin, Peña-Chilet, Maria, Gutierrez, Antonio, Collini, Paola, Karanian, Marie, Redondo, Andres, Lopez-Pousa, Antonio, Grignani, Giovanni, Diaz-Martin, Juan, Marcilla, David, Fernandez-Serra, Antonio, Gonzalez-Aguilera, Cristina, Casali, Paolo G, Blay, Jean-Yves, and Stacchiotti, Silvia

Published
2020
Full Text
View/download PDF

15. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial

Author

Stacchiotti, Silvia, Ferrari, Stefano, Redondo, Andres, Hindi, Nadia, Palmerini, Emanuela, Vaz Salgado, Maria Angeles, Frezza, Anna Maria, Casali, Paolo Giovanni, Gutierrez, Antonio, Lopez-Pousa, Antonio, Grignani, Giovanni, Italiano, Antoine, LeCesne, Axel, Dumont, Sarah, Blay, Jean Yves, Penel, Nicolas, Bernabeu, Daniel, de Alava, Enrique, Karanian, Marie, Morosi, Carlo, Brich, Silvia, Dagrada, Gian Paolo, Vallacchi, Viviana, Castelli, Chiara, Brenca, Monica, Racanelli, Dominga, Maestro, Roberta, Collini, Paola, Cruz, Josefina, and Martin-Broto, Javier

Published
2019
Full Text
View/download PDF

16. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Author

Bouzid, Kamel, Campone, Mario, Coudert, Bruno, Nowecki, Zbigniew, Errihani, Hassan, Dalenc, Florence, Ferreira, Ana, Mano, Max, Ricci, Francesco, Kalofonos, Haralabos, Andreetta, Claudia, Montemurro, Filippo, Barrett, Sophie, Zhang, Qingyuan, Mavroudis, Dimitris, Matus, Juan, Beato, Carlos, Hu, Xichun, Gaafar, Rabab, Abdel Azeem, Hamdy, Perrin, Christophe, Ettl, Johannes, Lang, Istvan, Verma, Sunil, Li, Huiping, Brain, Etienne, Hoffmann, Oliver, Cariello, Anna, Tondini, Carlo, Altwegeiri, Taher, Loman, Niklas, Lux, Michael, Frassoldati, Antonio, Aziz, Zeba, Salas, Fernando, Streb, Joanna, Wronski, Andrzej, Menjón Beltrán, Salomón, Cicin, Irfan, Schmid, Peter, Laing, Robert, Tong, Zhongsheng, Boer, Katalin, Juhasz, Balazs, Gianni, Luca, Curigliano, Giuseppe, Juarez, Alejandro, Susnjar, Snezana, Matos, Erika, Uslu, Ruchan, Wildiers, Hans, Cruz, Marcelo, Bourgeois, Hugues, von Schumann, Raquel, Stemmer, Salomón, Vásquez, Flavia Morales, Dominguez, Adriana, Wojtukiewicz, Marek, Trifunovic, Jasna, Illarramendi, Jose Juan, Garcia, Laura, Peron, Yann Izarzugaza, Echarri, Maria Jose, Voitko, Natliia, Wheatley, Duncan, Waters, Simon, De Boer, Richard, Jerusalem, Guy, Cocquyt, Véronique, Barrios, Carlos, Panasci, Lawrence, Mattson, Johanna, Tanner, Minna, Gozy, Michel, Vasilopoulos, Georgios, Revesz, Janos, Latini, Luciano, Gridelli, Cesare, Lazaro, Jesus, Gonzalez, Antonio, Barnadas Molins, Agusti, Martinez, Eduardo, Alarcón, Jesús, Arance, Ana, Klint, Leif, Kovalyov, Oleksiy, Baird, Richard, Yeo, Belinda, McCarthy, Nicole, Greil, Richard, Wang, Shusen, Artignan, Xavier, Augereau, Paule, Juhasz-Boess, Ingolf, Ngan, Roger, Goldberg, Hadassah, Di Costanzo, Francesco, Ferraù, Francesco, Aleknavicius, Eduardas, Rashid, Kamran, Costa, Luís, Angel Garcia, Jose, de la Cruz, Luis Ruiz, López López, Rafael, Del Val, Olga, Ozyilkan, Ozgur, Azribi, Fathi, Verrill, Mark, Turner, Nicholas, Beith, Jane, Petzer, Andreas, Andrade, Jurandyr, Bernstein, Vanessa, Rayson, Daniel, Saad Eldin, Ibtessam, Achille, Mihaëla, Mueller, Volkmar, Gennari, Alessandra, Cascinu, Stefano, Ghosn, Marwan, El-Saghir, Nagi, Van den Bosch, Joan, Oosterkamp, Rianne, Kukulska, Monika, Pelaez, Ignacio, Hernandez, Carolina, del Mar Gordon, Maria, Dalmau, Elsa, Alonso, Jose Luis, Aksoy, Sercan, Coskun, Hasan Senol, Shparyk, Yaroslav, Varughese, Mohini, Panwar, Udaiveer, Barraclough, Lisa, Levitt, Nicola, Hicks, Jonathan, Rigg, Anna, Allen, Mark, Castillo, Cecila, Fein, Luis Enrique, Stuart-Harris, Robin, Singer, Christian, Stoeger, Herbert, Smiljanic, Sasha, Feng, Jifeng, Cedeño, Miguel, Berdah, Jean Francois, Orfeuvre, Hubert, Goncalves, Anthony, Grischke, Eva-Maria, Simon, Eike, Wagner, Steffen, Efremidou, Anna, Papazisis, Konstantinos, Evron, Ella, Inbar, Moshe, Baruch, Noa Ben, Geffen, David, Karminsky, Natalya, Ruggeri, Enzo Maria, Luigi, Cavanna, Grasso, Donatella, Juozaityte, Elona, Rafael Rodriguez Cid, Jeronimo, Roerdink, Henk, Siddiqi, Neelum, Passos Coelho, José Luís, Garre, Elisa Garcia, Garcia, Andres, Martínez Jañez, Noelia, Lopez Ceballos, Maria Helena, Mele, Mireia, García, María, Arcediano, Alberto, McAdam, Karen, Perren, Timothy, Taylor, Wendy, Humphreys, Alison, Vera, Raul, Kaen, Luis Alberto, Steger, Günther, Andel, Johannes, de Grève, Jacques, Huizing, Manon, Hegg, Roberto, Joy, Anil, Sehdev, Sandeep, Kütner, Riina, Ruohola, Johanna, Dohollou, Nadine, Grosjean, Jessica, Laplaige, Philippe, Largillier, Rémy, Martin, Philippe, Pottier, Virginie, Alexandre, Jerome, Christensen, Bernd, Zahm, Dirk-Michael, Khandan, Fariba, Lueck, Hans-Joachim, Fountzilas, Georgios, Fried, Georgeta, Giacobino, Alice, Bonetti, Andrea, Guerra, Yanin Chavarri, Van Warmerdam, Laurens, Van der Velden, Annette, Vrijaldenhoven, Suzan, de Jongh, Felix, Cavero, Milagros, Andres Conejero, Raquel, Murias, Adolfo, Saura, Salvador, Oltra, Amparo, Redondo, Andres, Ribelles, Nuria, Bachmeier, Kilian, Joffe, Johnathan, Chakraborti, Prabir, Beresford, Mark, Butt, Mohammad, Poole, Christopher, Yordi, Gassan, Woodward, Natasha, Amorim, Gilberto, Califaretti, Nadia, Fox, Susan, Robidoux, Andre, Li, NanLi, Li, Nenxiao, Jiang, Jun, Soria, Tannia, Padrik, Peeter, Saarni, Outi, Genet, Dominique, Catala, Stéphanie, Barletta, Hugues, Teixeira, Luis, Facchini, Thomas, Hesse, Tobias, Kühn, Thorsten, Ober, Angelika, Repp, Roland, Schroeder, Willibald, Pectasides, Dimitrios, Bodoky, Gyorgy, Kahan, Zsuzsanna, Jiveliouk, Irina, Rosengarten, Ora, Alabiso, Oscar, Perez, Mario, Van de Wouw, Yes, Smok-Kalwat, Jolanta, Damasceno, Margarida, Sousa, Gabriela, Abulkhair, Omalkhair, Antón Torres, Antonio, Martinez, Maria Purificación, Garcia Mata, Jesús, Jesús Florián Jerico, Marta Santisteban, Llombart, Antonio, Sanchez, Rosa, Torrego, Juan Carlos, Garate, Clara Olier, Rodriguez, Cesar, Llorente, Rosa, de Prado, Diego Soto, Cortés, Javier, Llorca, Cristina, Galán, Antonio, Viñas Villaro, Gemma, Narbe, Ulrik, Bjömeklett, Helena Granstam, Westwell, Sarah, Newby, Jackie, Jafri, Mariam, Rodríguez, Robinson, Alonso, Isabel, Bachelot, T., Ciruelos, E., Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Bondarenko, I., Paluch-Shimon, S., Wardley, A., Merot, J.-L., du Toit, Y., Easton, V., Lindegger, N., and Miles, D.

Published
2019
Full Text
View/download PDF

18. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

Author

González-Martín, Antonio, Pothuri, Bhavana, Vergote, Ignace, Christensen, René DePont, Graybill, Whitney, Mirza, Mansoor R., McCormick, Colleen, Lorusso, Domenica, Hoskins, Paul, Freyer, Gilles, Baumann, Klaus, Jardon, Kris, Redondo, Andrés, Moore, Richard G., Vulsteke, Christof, OʼCearbhaill, Roisin E., Lund, Bente, Backes, Floor, Barretina-Ginesta, Pilar, Haggerty, Ashley F., Rubio-Pérez, Maria J., Shahin, Mark S., Mangili, Giorgia, Bradley, William H., Bruchim, Ilan, Sun, Kaiming, Malinowska, Izabela A., Li, Yong, Gupta, Divya, and Monk, Bradley J.

Published
2020
Full Text
View/download PDF

20. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2

Author

Monk, Bradley J., Poveda, Andrés, Vergote, Ignace, Raspagliesi, Francesco, Fujiwara, Keiichi, Bae, Duk-Soo, Oaknin, Ana, Ray-Coquard, Isabelle, Provencher, Diane M., Karlan, Beth Y., Lhommé, Catherine, Richardson, Gary, Rincón, Dolores Gallardo, Coleman, Robert L., Marth, Christian, Brize, Arija, Fabbro, Michel, Redondo, Andrés, Bamias, Aristotelis, Ma, Haijun, Vogl, Florian D., Bach, Bruce A., and Oza, Amit M.

Published
2016
Full Text
View/download PDF

21. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

Author

Lorusso, Domenica, Hilpert, Felix, González Martin, Antonio, Rau, Joern, Ottevanger, Petronella, Greimel, Elfriede, Lück, Hans-Joachim, Selle, Frédéric, Colombo, Nicoletta, Kroep, Judith R, Mirza, Mansoor R, Berger, Regina, Pardo, Beatriz, Grischke, Eva-Maria, Berton-Rigaud, Dominique, Martinez-Garcia, Jeronimo, Vergote, Ignace, Redondo, Andrés, Cardona, Andrés, Bastière-Truchot, Lydie, du Bois, Andreas, and Kurzeder, Christian

Published
2019
Full Text
View/download PDF

22. Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus.

Author

Redondo, Andrés, Barretina, Pilar, Pérez-Fidalgo, Alejandro, Rubio, María Jesús, and González-Martín, Antonio

Subjects
*DELPHI method, *OVARIAN cancer, *POLY(ADP-ribose) polymerase, *LIKERT scale, *ADENOSINES
Abstract

Objective: Our aim was to reach a consensus on the management of the most controversial issues of advanced ovarian cancer. Methods: Nominal group and Delphi techniques were used. A steering committee of 5 experts analyzed current management of advanced ovarian cancer, identified controversies, critically analyzed the evidence, and formulated guiding statements for clinicians. Subsequently, a panel of 15 experts was selected to test agreement with the statements through two Delphi rounds. Items were scored on a 4-point Likert scale from 1 (totally disagree) to 4 (totally agree). In the first and second rounds, consensus was considered if ≥70% of answers pertained to category 1 or category 4. Results: Overall, 112 statements were incorporated in the following areas: 1) biomarkers and hereditary ovarian cancer; 2) first-line treatment; 3) recurrent disease when platinum might be the best option; and 4) post-poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors setting. In the first Delphi round, 37 statements reached consensus and did thus not pass to the second round. After the second round, another 18 statements reached consensus. Forty-six of the consensus were with the agreement and 9 with the disagreement. Conclusion: Through the methodology used, a consensus was reached in approximately half of the statements. The results of this work may be useful in addressing the most controversial issues on the management of advanced ovarian cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

Author

Monk, Bradley J, Poveda, Andrés, Vergote, Ignace, Raspagliesi, Francesco, Fujiwara, Keiichi, Bae, Duk-Soo, Oaknin, Ana, Ray-Coquard, Isabelle, Provencher, Diane M, Karlan, Beth Y, Lhommé, Catherine, Richardson, Gary, Rincón, Dolores Gallardo, Coleman, Robert L, Herzog, Thomas J, Marth, Christian, Brize, Arija, Fabbro, Michel, Redondo, Andrés, Bamias, Aristotelis, Tassoudji, Marjan, Navale, Lynn, Warner, Douglas J, and Oza, Amit M

Published
2014
Full Text
View/download PDF

25. Evaluation of Immune Infiltrates in Ovarian Endometriosis and Endometriosis-Associated Ovarian Cancer: Relationship with Histological and Clinical Features.

Author

Spagnolo, Emanuela, Martinez, Alejandra, Mascarós-Martínez, Andrea, Marí-Alexandre, Josep, Carbonell, María, González-Cantó, Eva, Pena-Burgos, Eva Manuela, Mc Cormack, Bárbara Andrea, Tomás-Pérez, Sarai, Gilabert-Estellés, Juan, López-Carrasco, Ana, Hidalgo, Paula, Ángeles, Martina Aida, Redondo, Andrés, Gallego, Alejandro, and Hernández, Alicia

Subjects
T-cell exhaustion, TUMOR-infiltrating immune cells, OVARIAN cancer, ENDOMETRIOSIS, PROGRESSION-free survival, IMMUNOCHEMISTRY
Abstract

Background: the association between ovarian endometriosis (OE) and endometriosis-associated ovarian cancer (EAOC) is extensively documented, and misfunction of the immune system might be involved. The primary objective of this study was to identify and compare the spatial distribution of tumour-infiltrating lymphocytes (TILs) and tumour-associated macrophages (TAMs) in OE and EAOC. Secondary objectives included the analysis of the relationship between immunosuppressive populations and T-cell exhaustion markers in both groups. Methods: TILs (CD3, CD4, and CD8) and macrophages (CD163) were assessed by immunochemistry. Exhaustion markers (PD-1, TIM3, CD39, and FOXP3) and their relationship with tumour-associated macrophages (CD163) were assessed by immunofluorescence on paraffin-embedded samples from n = 43 OE and n = 54 EAOC patients. Results: we observed a predominantly intraepithelial CD3+ distribution in OE but both an intraepithelial and stromal pattern in EAOC (p < 0.001). TILs were more abundant in OE (p < 0.001), but higher TILs significantly correlated with a longer overall survival and disease-free survival in EAOC (p < 0.05). CD39 and FOXP3 significantly correlated with each other and CD163 (p < 0.05) at the epithelial level in moderate/intense CD4 EAOC, whereas in moderate/intense CD8+, PD-1+ and TIM3+ significantly correlated (p = 0.009). Finally, T-cell exhaustion markers FOXP3-CD39 were decreased and PD-1-TIM3 were significantly increased in EAOC (p < 0.05). Conclusions: the dysregulation of TILs, TAMs, and T-cell exhaustion might play a role in the malignization of OE to EAOC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma—A Study by the Spanish Group for Ovarian Cancer Research (GEICO).

Author

Pizarro, David, Romero, Ignacio, Pérez-Mies, Belén, Redondo, Andrés, Caniego-Casas, Tamara, Carretero-Barrio, Irene, Cristóbal, Eva, Gutiérrez-Pecharromán, Ana, Santaballa, Ana, D'Angelo, Emanuela, Hardisson, David, Vieites, Begoña, Matías-Guiu, Xavier, Estévez, Purificación, Guerra, Eva, Prat, Jaime, Poveda, Andrés, López-Guerrero, José Antonio, and Palacios, José

Subjects
PROGRAMMED cell death 1 receptors, TUMOR-infiltrating immune cells, PROGRAMMED death-ligand 1, OVARIAN cancer, BRCA genes, CANCER research
Abstract

Early stages are under-represented in studies on the molecular and immune features of high-grade serous ovarian carcinoma (HGSOC), and specific studies focused on early-stage HGSOC are required for a better prognostic stratification and to personalize chemotherapy. The aim of this study was to determine the prognostic significance of CD8+ and CD4+ tumor-infiltrating lymphocytes (TILs), tumoral cell PD-L1 expression, BRCA mutational status and tumor mutation burden (TMB) in early-stage HGSOC. A retrospective study was performed on stage I and II HGSOC from the Molecular Reclassification of Early Stages of Ovarian Cancer (RECLAMO) cohort from the Spanish Group of Ovarian Cancer Research (GEICO). Centralized histological typing was performed based on morphological and immunohistochemical features. Intraepithelial (i) and stromal (s) CD8+ and CD4+ T cells and PD-L1 were evaluated on tissue microarrays by immunohistochemistry. BRCA1 and BRCA2 mutation status and TMB were analyzed in tumor DNA using next-generation sequencing. The study included 124 tumors. High iCD8+ (>20 TILs/core), low/intermediate CD4+ (<20 TILs/core) and high CD8+/CD4+ ratio (>35/core) were associated with favorable outcomes. Tumor cell PD-L1 expression (TPS ≥ 1) was present in only 8% of tumors. In total, 11 (16%) and 6 (9%) out of 69 HGSOC tested carried pathogenic or likely pathogenic BRCA1 or BRCA2 mutations, respectively. Median TMB of 40 tumors analyzed was 5.04 mutations/Mb and only 6 tumors had 10 or more mutations/Mb. BRCA status and TMB were not associated with TILs or prognosis. When compared with studies on advanced HGSOC, our results suggested that prognostic variables differed according to stage and that more studies focused on early stages of HGSOC are needed to better stratify these tumors. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Author

Mirza, Mansoor R., Monk, Bradley J., Herrstedt, Jørn, Oza, Amit M., Mahner, Sven, Redondo, Andrés, Fabbro, Michel, Ledermann, Jonathan A., Lorusso, Domenica, Vergote, Ignace, Ben-Baruch, Noa E., Marth, Christian, Mądry, Radoslaw, Christensen, René D., Berek, Jonathan S., Dørum, Anne, Tinker, Anna V., du Bois, Andreas, González-Martín, Antonio, Follana, Philippe, Benigno, Benedict, Rosenberg, Per, Gilbert, Lucy, Rimel, Bobbie J., Buscema, Joseph, Balser, John P., Agarwal, Shefali, and Matulonis, Ursula A.

Published
2017
Full Text
View/download PDF

29. Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS)

Author

Rubió-Casadevall, Jordi, Martinez-Trufero, Javier, Garcia-Albeniz, Xabier, Calabuig, Silvia, Lopez-Pousa, Antonio, del Muro, Javier Garcia, Fra, Joaquin, Redondo, Andrés, Lainez, Nuria, Poveda, Andrés, Valverde, Claudia, De Juan, Ana, Sevilla, Isabel, Casado, Antonio, Andres, Raquel, Cruz, Josefina, Martin-Broto, Javier, Maurel, Joan, and the Spanish Group for Research on Sarcoma (GEIS)

Published
2015
Full Text
View/download PDF

33. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial.

Author

Barretina-Ginesta, Maria-Pilar, Monk, Bradley J., Han, Sileny, Pothuri, Bhavana, Auranen, Annika, Chase, Dana M., Lorusso, Domenica, Anderson, Charles, Abadie-Lacourtoisie, Sophie, Cloven, Noelle, Braicu, Elena I., Amit, Amnon, Redondo, Andrés, Shah, Ruchit, Kebede, Nehemiah, Hawkes, Carol, Gupta, Divya, Woodward, Tatia, O'Malley, David M., and González-Martín, Antonio

Abstract

Background: The PRIMA phase 3 trial showed niraparib significantly prolongs median progression-free survival (PFS) versus placebo in patients with advanced ovarian cancer (OC) responsive to first-line platinum-based chemotherapy, including those who had tumors with homologous recombination deficiency (HRd). This analysis of PRIMA examined the qualityadjusted PFS (QA-PFS) and quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) of patients on maintenance niraparib versus placebo. Methods: Patients were randomized 2:1 to receive once-daily maintenance niraparib (n = 487) or placebo (n = 246). QA-PFS was defined as the PFS of patients adjusted for their health-related quality of life (HRQoL) prior to disease progression, measured using European Quality of Life Five-Dimension (EQ-5D) questionnaire index scores from the PRIMA trial. Q-TWiST was calculated by combining data on PFS, duration of symptomatic grade X2 adverse events (fatigue or asthenia, nausea, vomiting, abdominal pain, and abdominal bloating) prior to disease progression, and EQ-5D index scores. Analyses used data collected up to the last date of PFS assessment (May 17, 2019). Results: The restricted mean QA-PFS was significantly longer with niraparib versus placebo in the HRd (n = 373) and overall intention-to-treat (ITT; n = 733) populations (mean gains of 6.5 [95% confidence interval; CI, 3.9-8.9] and 4.1 [95% CI, 2.2-5.8] months, respectively). There were also significant improvements in restricted mean Q-TWiST for niraparib versus placebo (mean gains of 5.9 [95% CI, 3.5-8.6] and 3.5 [95% CI, 1.7-5.6] months, respectively) in the HRd and ITT populations. Conclusions: In patients with advanced OC, first-line niraparib maintenance was associated with significant gains in QA-PFS and Q-TWiST versus placebo. These findings demonstrate that niraparib maintenance treatment is associated with a PFS improvement and that treatment benefit is maintained even when HRQoL and/or toxicity data are combined with PFS in a single measure. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

34. Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib.

Author

Hidalgo-Ríos, Samuel, Carrillo-García, Jaime, Moura, David S., Stacchiotti, Silvia, López-Pousa, Antonio, Redondo, Andrés, Italiano, Antoine, Gutiérrez, Antonio, Grignani, Giovanni, Hindi, Nadia, López-Guerrero, José-Antonio, Muro, Xavier García del, Trufero, Javier Martínez, Palmerini, Emanuela, García, Ana Sebio, Bernabeu, Daniel, Le Cesne, Axel, Casali, Paolo Giovanni, Blay, Jean-Yves, and Cruz Jurado, Josefina

Subjects
MESENCHYME tumors, INFLAMMATION, MULTIVARIATE analysis, INDEPENDENT variables, RETROSPECTIVE studies, METASTASIS, PROTEIN-tyrosine kinase inhibitors, NEUTROPHIL lymphocyte ratio, DESCRIPTIVE statistics, ERYTHROCYTES, TUMOR markers
Abstract

Simple Summary: Pazopanib treatment in advanced solitary fibrous tumour patients, assessed in the prospective GEIS-32 phase II clinical trial, has shown longer progression-free survival and overall survival versus chemotherapy treatment in control patients. In recent years, the interest in the prognostic and predictive value of different peripheral inflammatory indexes, such as neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and red cell distribution width, has been increased in sarcomas, showing significant results in different soft tissue sarcomas. However, they have not been previously analysed in solitary fibrous tumour (SFT) patients. These indexes were retrospectively analysed in the typical- and malignant-SFT cohorts treated with pazopanib of the GEIS-32 trial to evaluate their predictive or prognostic value. Pazopanib was assessed prospectively in the GEIS-32 phase II study (NCT02066285) on advanced solitary fibrous tumour (SFT), resulting in a longer progression-free survival (PFS) and overall survival (OS) compared with historical controls treated with chemotherapy. A retrospective analysis of peripheral inflammatory indexes in patients enrolled into GEIS-32 was performed to evaluate their prognostic and predictive value. Patients received pazopanib 800 mg/day as the first antiangiogenic line. The impacts of baseline neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and red cell distribution width (RDW) on PFS, OS, and Choi response were evaluated by univariate and multivariate analysis. Metastasis-free interval (MFI), mitotic count, and ECOG were also included as potential prognostic factors. Sixty-seven SFT patients, enrolled in this study, showed a median age of 63 years and a female/male distribution of 57/43. The median follow-up from treatment initiation was 16.8 months. High baseline NLR, PLR, and standardised RDW were significantly associated with worse PFS and OS. NLR, RDW, MFI, and mitotic count were independent variables for PFS, while RDW and ECOG were independent for OS. Further, NLR and mitotic count were independent factors for Choi response. High baseline NLR and RDW values were independent prognostic biomarkers for worse outcome in advanced SFT patients treated with pazopanib. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

36. Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (LBA 6)

Author

Matulonis, Ursula, Herrstedt, Jørn, Oza, Amit, Mahner, Sven, Redondo, Andres, Berton, Dominique, Berek, Jonathan, Haslund, Charlotte, Marmé, Frederik, González-Martín, Antonio, Becourt, Stéphanie, Tinker, Anna, Ledermann, Jonathan, Benigno, Benedict, Lindahl, Gabriel, Colombo, Nicoletta, Malinowska, Izabela, Liu, Wenlei, Schmitz, Michael, Monk, Bradley, and Mirza, Mansoor

Published
2023
Full Text
View/download PDF

39. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial

Author

Martín Broto, Javier, Hindi, Nadia, Grignani, Giovanni, Martínez Trufero, Javier, Redondo, Andrés, Valverde, Claudia, Encinas Tobajas, Víctor, Álava Casado, Enrique de, López Martín, José A., Universidad de Sevilla. Departamento de Citología e Histología Normal y Patológica, Universidad de Sevilla. Departamento de Farmacología, Pediatría y Radiología, and Universidad de Sevilla. CTS1035: Patología Molecular del Cáncer Sólido

Subjects
PD-1/ PD-L1 axis (nivolumab), Sarcomas, Test the double inhibition of angiogenesis (sunitinib), PD-1 inhibitors, Immune response
Abstract

Background: Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. As tumor angiogenesis promotes immunosuppression, we designed a phase Ib/II trial to test the double inhibition of angiogenesis (sunitinib) and PD-1/PD-L1 axis (nivolumab). Methods: This single-arm, phase Ib/II trial enrolled adult patients with selected subtypes of sarcoma. Phase Ib established two dose levels: level 0 with sunitinib 37.5mg daily from day 1, plus nivolumab 3mg/kg intravenously on day 15, and then every 2weeks; and level −1 with sunitinib 37.5mg on the first 14 days (induction) and then 25mg per day plus nivolumab on the same schedule. The primary endpoint was to determine the recommended dose for phase II (phase I) and the 6-month progression free survival rate, according to Response Evaluation Criteria in Solid Tumors 1.1 (phase II). Results: From May 2017 to April 2019, 68 patients were enrolled: 16 in phase Ib and 52 in phase II. The recommended dose of sunitinib for phase II was 37.5mg as induction and then 25mg in combination with nivolumab. After a median follow-up of 17months (4–26), the 6-month progression-free survival rate was 48% (95% CI 41% to 55%). The most common grade 3–4 adverse events included transaminitis (17.3%) and neutropenia (11.5%). Conclusions: Sunitinib plus nivolumab is an active scheme with manageable toxicity in the treatment of selected patients with advanced soft tissue sarcoma, with almost half of patients free of progression at 6months. GEIS ISG BMS Pfizer

Published
2020

40. Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models.

Author

Heredia-Soto, Victoria, Escudero, Javier, Miguel, María, Ruiz, Patricia, Gallego, Alejandro, Berjón, Alberto, Hernández, Alicia, Martínez-Díez, Marta, Zheng, Shuyu, Tang, Jing, Hardisson, David, Feliu, Jaime, Redondo, Andrés, and Mendiola, Marta

Subjects
CELL lines, PACLITAXEL, CELL cycle, TRABECTEDIN, CELL culture, ANTINEOPLASTIC agents
Abstract

Ovarian cancer (OC) is a life-threatening tumor and the deadliest among gynecological cancers in developed countries. First line treatment with a carboplatin/paclitaxel regime is initially effective in the majority of patients, but most advanced OC will recur and develop drug resistance. Therefore, the identification of alternative therapies is needed. In this study, we employed a panel of high-grade serous ovarian cancer (HGSOC) cell lines, in monolayer and three-dimensional cell cultures. We evaluated the effects of a novel tubulin-binding agent, plocabulin, on proliferation, cell cycle, migration and invasion. We have also tested combinations of plocabulin with several drugs currently used in OC in clinical practice. Our results show a potent antitumor activity of plocabulin, inhibiting proliferation, disrupting microtubule network, and decreasing their migration and invasion capabilities. We did not observe any synergistic combination of plocabulin with cisplatin, doxorubicin, gemcitabine or trabectedin. In conclusion, plocabulin has a potent antitumoral effect in HGSOC cell lines that warrants further clinical investigation. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

43. An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer

Author

Cejas Paloma, Feliu Jaime, Redondo Andrés, Zamora Pilar, San José Belén, López Rocío, Madero Rosario, Hardisson David, Pinto Álvaro, Gámez-Pozo Angelo, Sánchez-Navarro Iker, González Barón Manuel, Ángel Fresno Vara Juan, and Espinosa Enrique

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Gene expression profiling may improve prognostic accuracy in patients with early breast cancer. Our objective was to demonstrate that it is possible to develop a simple molecular signature to predict distant relapse. Methods We included 153 patients with stage I-II hormonal receptor-positive breast cancer. RNA was isolated from formalin-fixed paraffin-embedded samples and qRT-PCR amplification of 83 genes was performed with gene expression assays. The genes we analyzed were those included in the 70-Gene Signature, the Recurrence Score and the Two-Gene Index. The association among gene expression, clinical variables and distant metastasis-free survival was analyzed using Cox regression models. Results An 8-gene prognostic score was defined. Distant metastasis-free survival at 5 years was 97% for patients defined as low-risk by the prognostic score versus 60% for patients defined as high-risk. The 8-gene score remained a significant factor in multivariate analysis and its performance was similar to that of two validated gene profiles: the 70-Gene Signature and the Recurrence Score. The validity of the signature was verified in independent cohorts obtained from the GEO database. Conclusions This study identifies a simple gene expression score that complements histopathological prognostic factors in breast cancer, and can be determined in paraffin-embedded samples.

Published
2010
Full Text
View/download PDF

44. Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer

Author

Matulonis, Ursula, Herrstedt, Jørn, Oza, Amit, Mahner, Sven, Redondo, Andrés, Berton, Dominique, Berek, Jonathan, Lund, Bente, Marmé, Frederik, González-Martín, Antonio, Tinker, Anna, Ledermann, Jonathan, Benigno, Benedict, Lindahl, Gabriel, Colombo, Nicoletta, Li, Yong, Gupta, Divya, Monk, Bradley, and Mirza, Mansoor

Published
2021
Full Text
View/download PDF

46. Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer

Author

Conte, PierFranco, Schneeweiss, Andreas, Loibl, Sibylle, Mamounas, Eleftherios P., Minckwitz, Gunter, Mano, Max S., Untch, Michael, Huang, Chiun‐Sheng, Wolmark, Norman, Rastogi, Priya, D'Hondt, Veronique, Redondo, Andrés, Stamatovic, Ljiljana, Bonnefoi, Hervé, Castro‐Salguero, Hugo, Fischer, Hans H., Wahl, Tanya, Song, Chunyan, Boulet, Thomas, and Trask, Peter

Subjects
EPIDERMAL growth factor receptors, HORMONE receptor positive breast cancer, HUMAN growth, BREAST cancer, APPETITE loss, RESEARCH, IMMUNOGLOBULINS, CLINICAL trials, CARCINOGENESIS, RESEARCH methodology, CELL receptors, MEDICAL cooperation, EVALUATION research, COMPARATIVE studies, QUALITY of life, RESEARCH funding, QUESTIONNAIRES, COMBINED modality therapy, BREAST tumors
Abstract

Background: The phase 3 KATHERINE trial demonstrated significantly improved invasive disease-free survival with adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant chemotherapy plus HER2-targeted therapy.Methods: Patients who received taxane- and trastuzumab-containing neoadjuvant therapy (with/without anthracyclines) and had residual invasive disease (breast and/or axillary nodes) at surgery were randomly assigned to 14 cycles of adjuvant T-DM1 (3.6 mg/kg intravenously every 3 weeks) or trastuzumab (6 mg/kg intravenously every 3 weeks). The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and breast cancer module (QLQ-BR23) were completed at screening, at day 1 of cycles 5 and 11, within 30 days after study drug completion, and at 6- and 12-month follow-up visits.Results: Of patients who were randomly assigned to T-DM1 (n = 743) and trastuzumab (n = 743), 612 (82%) and 640 (86%), respectively, had valid baseline and ≥1 postbaseline assessments. No clinically meaningful changes (≥10 points) from baseline in mean QLQ-C30 and QLQ-BR23 scores occurred in either arm. More patients receiving T-DM1 reported clinically meaningful deterioration at any assessment point in role functioning (49% vs 41%), appetite loss (38% vs 28%), constipation (47% vs 38%), fatigue (66% vs 60%), nausea/vomiting (39% vs 30%), and systemic therapy side effects (49% vs 36%). These differences were no longer apparent at the 6-month follow-up assessment, except for role functioning (23% vs 16%).Conclusion: These data suggest that health-related quality of life was generally maintained in both study arms over the course of treatment. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

47. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Author

Mirza, Mansoor R, Monk, Bradley J, Herrstedt, Jørn, Oza, Amit M, Mahner, Sven, Redondo, Andrés, Fabbro, Michel, Ledermann, Jonathan A, Lorusso, Domenica, Vergote, Ignace, Ben-Baruch, Noa E, Marth, Christian, Madry, Radoslaw, Christensen, René D, Berek, Jonathan S, Dørum, Anne, Tinker, Anna V, du Bois, Andreas, González-Martín, Antonio, Follana, Philippe, Benigno, Benedict, Rosenberg, Per, Gilbert, Lucy, Rimel, Bobbie J, Buscema, Joseph, Balser, John P, Agarwal, Shefali, Matulonis, Ursula A, Lund, Bente, Malander, Susanne, Woie, Kathrine, Hellman, Kristina, Nøttrup, Trine Juhler, Havsteen, Hanne, Sehouli, Jalid, Harter, Philipp, Canzler, Ulrich, Lück, Hans-Joachim, Wölber, Linn, Marmé, Frederik, Meier, Werner, Heubner, Martin, Hilpert, Felix, Emons, Günter, Burges, Alexander, Bover Barcelo, Isabel Maria, Gil Martín, Marta, Palacio Vázquez, Isabel, Casado Herráez, Antonio, Maria del Campo, José, Lesoin, Anne, Berton-Rigaud, Dominique, N'Guyen, Thierry, Hardy-Bessard, Anne-Claire, Banerjee, Susana, Lord, Rosemary, Waters, Justin, Montes, Ana, Chan, Stephen, Williams, Sarah J, Barlow, Claire, Mullard, Anna, Colombo, Nicoletta, Scambia, Giovanni, Tognon, Germana, Scollo, Paolo, Kridelka, Frédéric, Leroy, Chantal, Debruyne, Philip, Huizing, Manon, Rosengarten, Ora, Levy, Talia, Frommer, Ronnie Shapira, Fishman, Ami, Edelman, David, Safra, Tamar, Amit, Amnon, Pikiel, Joanna, Suzin, Jacek, Mackowiak-Matejczyk, Beata, Reinthaller, Alexander, Petru, Edgar, Csoszi, Tibor, Bessette, Paul, Provencher, Diane, Lau, Susie, Ellard, Susan, Ghatage, Prafull, Moore, Kathleen, Wenham, Robert, Pineda, Mario, Azodi, Masoud, Mantia-Smaldone, Gina, Cloven, Noelle, Bailey, Cheryl, Lee, Christine, Secord, Angeles, Patel, Manish, Method, Michael, Callahan, Michael, Veena, John, Chan, John, Zarwan, Corrine, DiSilvestro, Paul, Teneriello, Michael, Gupta, Divya, Geller, Melissa, Burris, Howard, Slomovitz, Brian, Hendrickson, Andrea Wahner, McCormick, Colleen, Hanjani, Parviz, Blank, Stephanie, Haluska, Paul, Matei, Daniela, Vasilev, Stephen, Neidhart, Jeffrey, Boente, Matthew, Tchabo, Nana, Miller, David, and Targeted Gynaecologic Oncology (TARGON)

Subjects
0301 basic medicine, Oncology, Medizin, Genes, BRCA1, Platinum Compounds, POLY(ADP-RIBOSE) POLYMERASE, Kaplan-Meier Estimate, 030226 pharmacology & pharmacy, chemistry.chemical_compound, 0302 clinical medicine, Piperidines, Maintenance therapy, Bone Marrow, Medicine, Merck Sharp & Dohme, Homologous Recombination, Indazoles/adverse effects, Ovarian Neoplasms, Aged, 80 and over, Platinum compounds, OLAPARIB, Ovarian Neoplasms/drug therapy, Obstetrics and Gynecology, Bone Marrow/drug effects, General Medicine, Middle Aged, SOLID TUMORS, BRCA MUTATION CARRIERS, 030220 oncology & carcinogenesis, TRIAL, Female, Platinum sensitive, Adult, Piperidines/adverse effects, medicine.medical_specialty, Indazoles, Adolescent, Antineoplastic Agents, Disease-Free Survival, Olaparib, Maintenance Chemotherapy, Young Adult, 03 medical and health sciences, Platinum Compounds/therapeutic use, Double-Blind Method, Internal medicine, Humans, Rucaparib, Germ-Line Mutation, Aged, Neoplasm Staging, Cancer och onkologi, business.industry, Antineoplastic Agents/adverse effects, NEGATIVE BREAST-CANCER, 030104 developmental biology, chemistry, Recurrent Ovarian Cancer, Cancer and Oncology, Johnson Johnson, business
Abstract

BACKGROUND Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought to evaluate the efficacy of niraparib versus placebo as maintenance treatment for patients with platinum-sensitive, recurrent ovarian cancer. METHODS In this randomized, double-blind, phase 3 trial, patients were categorized according to the presence or absence of a germline BRCA mutation (gBRCA cohort and non-gBRCA cohort) and the type of non-gBRCA mutation and were randomly assigned in a 2: 1 ratio to receive niraparib (300 mg) or placebo once daily. The primary end point was progression-free survival. RESULTS Of 553 enrolled patients, 203 were in the gBRCA cohort (with 138 assigned to niraparib and 65 to placebo), and 350 patients were in the non-gBRCA cohort (with 234 assigned to niraparib and 116 to placebo). Patients in the niraparib group had a significantly longer median duration of progression-free survival than did those in the placebo group, including 21.0 vs. 5.5 months in the gBRCA cohort (hazard ratio, 0.27; 95% confidence interval [CI], 0.17 to 0.41), as compared with 12.9 months vs. 3.8 months in the non-gBRCA cohort for patients who had tumors with homologous recombination deficiency (HRD) (hazard ratio, 0.38; 95% CI, 0.24 to 0.59) and 9.3 months vs. 3.9 months in the overall non-gBRCA cohort (hazard ratio, 0.45; 95% CI, 0.34 to 0.61; P amp;lt; 0.001 for all three comparisons). The most common grade 3 or 4 adverse events that were reported in the niraparib group were thrombocytopenia (in 33.8%), anemia (in 25.3%), and neutropenia (in 19.6%), which were managed with dose modifications. CONCLUSIONS Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity. (Funded by Tesaro; ClinicalTrials.gov number, NCT01847274.) Funding Agencies|Tesaro; Amgen; Genentech; Roche; AstraZeneca; Myriad Genetics; Merck; Gradalis; Cerulean; Vermillion; ImmunoGen; Pfizer; Bayer; Nu-Cana BioMed; INSYS Therapeutics; GlaxoSmithKline; Verastem; Mateon Therapeutics; Pharmaceutical Product Development; Clovis Oncology; Janssen/Johnson Johnson; Eli Lilly; Merck Sharp Dohme

Published
2016

48. Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study.

Author

Redondo, Andrés, Vázquez, Manuel Ramos, Manso, Luis, Gil, Miguel J Gil, Llinas, Isabel Garau, García-Garre, Elisa, Rodríguez, César A, Chacón, José Ignacio, and López-Vivanco, Guillermo

Subjects
*METASTATIC breast cancer, *BREAST cancer patients, *BEVACIZUMAB, *BREAST cancer treatment, BREAST cancer chemotherapy
Abstract

Background: Randomized controlled trials of the first-line combination of bevacizumab and chemotherapy in patients with metastatic breast cancer (MBC) have shown improvements in tumor response and progression-free survival (PFS). Objective: The aim of this ambispective, observational study (LORENA) was to describe the clinical characteristics of long-term responders to bevacizumab-based therapy. Patients and methods: This study consisted of a retrospective and a prospective phase. During the retrospective phase, patients with HER2-negative MBC who were treated with bevacizumab-based first-line therapy were included. During the prospective phase, patients with PFS of ≥12 months were treated according to routine clinical practice procedures. Overall survival (OS) and PFS were estimated using the Kaplan–Meier method. Univariate and multivariate analyses of prognostic factors were performed. Results: In total, 148 women were included (median age: 50 years; range: 29–81 years). The mean duration of exposure to bevacizumab was 18 months. The majority of patients experienced objective response (complete: 23%; partial: 57%). Median PFS was 22.7 months and median OS was 58.2 months. In multivariate analyses, patients receiving maintenance hormonal therapy (MHT) had longer PFS (P=0.002; hazard ratio [HR] =1.8) and OS (P=0.009; HR=2.0), while patients not previously treated with taxanes had longer OS (P [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

49. Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer.

Author

Peláez-García, Alberto, Yébenes, Laura, Berjón, Alberto, Angulo, Antonia, Zamora, Pilar, Sánchez-Méndez, José Ignacio, Espinosa, Enrique, Redondo, Andrés, Heredia-Soto, Victoria, Mendiola, Marta, Feliú, Jaime, and Hardisson, David

Subjects
HORMONE receptor positive breast cancer, CANCER invasiveness, GENE expression, FORMALDEHYDE, SET theory
Abstract

Purpose: To compare the concordance in risk classification between the EndoPredict and the MammaPrint scores obtained for the same cancer samples on 40 estrogen-receptor positive/HER2-negative breast carcinomas. Methods: Formalin-fixed, paraffin-embedded invasive breast carcinoma tissues that were previously analyzed with MammaPrint as part of routine care of the patients, and were classified as high-risk (20 patients) and low-risk (20 patients), were selected to be analyzed by the EndoPredict assay, a second generation gene expression test that combines expression of 8 genes (EP score) with two clinicopathological variables (tumor size and nodal status, EPclin score). Results: The EP score classified 15 patients as low-risk and 25 patients as high-risk. EPclin re-classified 5 of the 25 EP high-risk patients into low-risk, resulting in a total of 20 high-risk and 20 low-risk tumors. EP score and MammaPrint score were significantly correlated (p = 0.008). Twelve of 20 samples classified as low-risk by MammaPrint were also low-risk by EP score (60%). 17 of 20 MammaPrint high-risk tumors were also high-risk by EP score. The overall concordance between EP score and MammaPrint was 72.5% (κ = 0.45, (95% CI, 0.182 to 0.718)). EPclin score also correlated with MammaPrint results (p = 0.004). Discrepancies between both tests occurred in 10 cases: 5 MammaPrint low-risk patients were classified as EPclin high-risk and 5 high-risk MammaPrint were classified as low-risk by EPclin and overall concordance of 75% (κ = 0.5, (95% CI, 0.232 to 0.768)). Conclusions: This pilot study demonstrates a limited concordance between MammaPrint and EndoPredict. Differences in results could be explained by the inclusion of different gene sets in each platform, the use of different methodology, and the inclusion of clinicopathological parameters, such as tumor size and nodal status, in the EndoPredict test. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

50. Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.

Author

Martin-Broto, Javier, Pousa, Antonio López, de las Peñas, Ramón, del Muro, Xavier García, Gutierrez, Antonio, Martinez-Trufero, Javier, Cruz, Josefina, Alvarez, Rosa, Cubedo, Ricardo, Redondo, Andrés, Maurel, Joan, Carrasco, Juan A., López-Martin, José A., Sala, Ángeles, Meana, José Andrés, Ramos, Rafael, Martinez-Serra, Jordi, Lopez-Guerrero, José A., Sevilla, Isabel, and Balaña, Carmen

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results